<p>Celcuity, Inc.（纳斯达克代码：CELC - 获取免费报告）的股票在覆盖该公司的十家研究机构中获得了 “适度买入” 的平均评级，Marketbeat Ratings 报告称。一位分析师对该股票给予了卖出建议，一位给予了持有建议，而八位则给予了买入建议。在过去一年中，更新了对该股票覆盖的经纪公司中，平均的十二个月目标价为 108.6250 美元。</p>
<ul>
<li>你会希望在 2026 年前购买的 3 只股票</li>
</ul>
<p>多家研究分析师对 CELC 股票发表了评论。富国银行在 12 月 12 日（星期五）的一份研究报告中开始覆盖 Celcuity。他们对该股票给予了 “增持” 评级，并设定了 126.00 美元的目标价。Needham &amp; Company LLC 在 3 月 10 日（星期二）的一份研究报告中将 Celcuity 的目标价从 95.00 美元上调至 122.00 美元，并给予该股票 “买入” 评级。HC Wainwright 在 11 月 17 日（星期一）的一份研究报告中重申了 “中性” 评级，并将 Celcuity 的目标价设定为 94.00 美元（上调自 77.00 美元）。Wolfe Research 在周四重申了 “跑赢大盘” 的评级，并对 Celcuity 的股票设定了 110.00 美元的目标价。最后，Jefferies Financial Group 在 12 月 2 日（星期二）的一份研究报告中将 Celcuity 的目标价从 108.00 美元上调至 134.00 美元，并给予该股票 “买入” 评级。</p>
<p><strong>获取我们对 Celcuity 的最新分析</strong></p>
<h2>Celcuity 价格表现</h2>
<p>CELC 股票在周一开盘价为 114.22 美元。Celcuity 的 1 年最低价为 7.57 美元，1 年最高价为 120.32 美元。该公司的流动比率为 12.26，速动比率为 12.26，债务与股本比率为 2.74。该公司的 50 日移动平均线为 108.80 美元，200 日移动平均线为 87.35 美元。该公司的市值为 52.8 亿美元，市盈率为-31.12，贝塔值为 0.38。</p>
<h2>内部交易活动</h2>
<p>在其他新闻中，董事 David Dalvey 在 1 月 27 日（星期二）出售了 20,000 股 Celcuity 股票，交易平均价格为 120.03 美元，总交易额为 2,400,600.00 美元。出售完成后，该董事在公司持有 90,000 股，价值 10,802,700 美元。此次交易使其持股减少了 18.18%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接获取。公司内部人士持有公司股票的 15.78%。</p>
<h2>对 Celcuity 的对冲基金看法</h2>
<p>多家对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Creative Planning 在第二季度获得了 Celcuity 的新股份，价值 177,000 美元。Intech Investment Management LLC 在第二季度将其在 Celcuity 的股份提高了 5.2%。Intech Investment Management LLC 目前持有 14,855 股该公司的股票，价值 198,000 美元，此前在该期间又购买了 734 股。Rhumbline Advisers 在第二季度将其在 Celcuity 的持股增加了 1.2%。Rhumbline Advisers 目前持有 42,697 股该公司的股票，价值 570,000 美元，此前在上个季度又购买了 503 股。XTX Topco Ltd 在第二季度获得了 Celcuity 的新股份，价值 169,000 美元。最后，Saturn V Capital Management LP 在第二季度将其在 Celcuity 的持股增加了 8.4%。Saturn V Capital Management LP 目前持有 1,185,520 股该公司的股票，价值 15,827,000 美元，此前在该期间又购买了 91,843 股。63.33% 的股票由机构投资者持有。</p>
<h2>关于 Celcuity</h2>
<p>（获取免费报告）</p>
<p>Celcuity, Inc 是一家临床阶段的生物技术公司，专注于精准肿瘤学诊断。该公司开发和商业化预测性生物标志物检测，旨在识别哪些患者最有可能从靶向癌症疗法中受益。通过将肿瘤细胞的功能特征与分子分析相结合，Celcuity 旨在优化治疗选择并改善实体肿瘤患者的治疗效果。</p>
<p>Celcuity 的专有平台通过使用外部检测评估肿瘤细胞对各种治疗药物的敏感性，测量 DNA 损伤反应和其他关键通路。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Celcuity</li>
<li>每位退休储蓄者现在需要阅读的 8,000 美元黄金看涨期权</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
<li>埃隆·马斯克：这可能将 100 美元变成 100,000 美元</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>美国的黄金储备定价为 42 美元。真实价格为 6,000 美元以上。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Celcuity 吗？</h2>
<p>在你考虑 Celcuity 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Celcuity 并不在名单上。</p>
<p>虽然 Celcuity 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

标普全球医疗股指数 ETF - iShares

<p>Celcuity, Inc.（纳斯达克代码：CELC）获得了十家研究机构的 “适度买入” 共识推荐。分析师的评级包括一项卖出、一项持有和八项买入推荐。平均十二个月的目标价格为 108.63 美元。分析师最近的目标价格范围从 94.00 美元到 134.00 美元。Celcuity 的股票开盘价为 114.22 美元，市值为 52.8 亿美元。内部交易活动包括一位董事出售了 20,000 股。该公司专注于精准肿瘤学诊断，旨在优化癌症治疗结果</p>

<p>Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have received an average rating of &#34;Moderate Buy&#34; from the ten research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $108.6250.</p>
<div class="lb-trans"><p>Celcuity, Inc.（纳斯达克代码：CELC - 获取免费报告）的股票在覆盖该公司的十家研究机构中获得了 “适度买入” 的平均评级，Marketbeat Ratings 报告称。一位分析师对该股票给予了卖出建议，一位给予了持有建议，而八位则给予了买入建议。在过去一年中，更新了对该股票覆盖的经纪公司中，平均的十二个月目标价为 108.6250 美元。</p>
</div><ul>
<li>3 Stocks You’ll Wish You Bought Before 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>你会希望在 2026 年前购买的 3 只股票</li>
</ul>
</div><p>A number of research analysts have commented on CELC shares. Wells Fargo &amp; Company assumed coverage on Celcuity in a research report on Friday, December 12th. They issued an &#34;overweight&#34; rating and a $126.00 price objective on the stock. Needham &amp; Company LLC boosted their target price on Celcuity from $95.00 to $122.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, March 10th. HC Wainwright reaffirmed a &#34;neutral&#34; rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a research note on Monday, November 17th. Wolfe Research reiterated an &#34;outperform&#34; rating and issued a $110.00 price objective on shares of Celcuity in a research report on Thursday. Finally, Jefferies Financial Group lifted their price objective on Celcuity from $108.00 to $134.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, December 2nd.</p>
<div class="lb-trans"><p>多家研究分析师对 CELC 股票发表了评论。富国银行在 12 月 12 日（星期五）的一份研究报告中开始覆盖 Celcuity。他们对该股票给予了 “增持” 评级，并设定了 126.00 美元的目标价。Needham &amp; Company LLC 在 3 月 10 日（星期二）的一份研究报告中将 Celcuity 的目标价从 95.00 美元上调至 122.00 美元，并给予该股票 “买入” 评级。HC Wainwright 在 11 月 17 日（星期一）的一份研究报告中重申了 “中性” 评级，并将 Celcuity 的目标价设定为 94.00 美元（上调自 77.00 美元）。Wolfe Research 在周四重申了 “跑赢大盘” 的评级，并对 Celcuity 的股票设定了 110.00 美元的目标价。最后，Jefferies Financial Group 在 12 月 2 日（星期二）的一份研究报告中将 Celcuity 的目标价从 108.00 美元上调至 134.00 美元，并给予该股票 “买入” 评级。</p>
</div><p><strong>Get Our Latest Analysis on Celcuity</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Celcuity 的最新分析</strong></p>
</div><h2>Celcuity Price Performance</h2>
<div class="lb-trans"><h2>Celcuity 价格表现</h2>
</div><p>Shares of CELC stock opened at $114.22 on Monday. Celcuity has a 1 year low of $7.57 and a 1 year high of $120.32. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. The firm's 50 day moving average is $108.80 and its 200-day moving average is $87.35. The firm has a market capitalization of $5.28 billion, a price-to-earnings ratio of -31.12 and a beta of 0.38.</p>
<div class="lb-trans"><p>CELC 股票在周一开盘价为 114.22 美元。Celcuity 的 1 年最低价为 7.57 美元，1 年最高价为 120.32 美元。该公司的流动比率为 12.26，速动比率为 12.26，债务与股本比率为 2.74。该公司的 50 日移动平均线为 108.80 美元，200 日移动平均线为 87.35 美元。该公司的市值为 52.8 亿美元，市盈率为-31.12，贝塔值为 0.38。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares in the company, valued at $10,802,700. The trade was a 18.18% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Company insiders own 15.78% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事 David Dalvey 在 1 月 27 日（星期二）出售了 20,000 股 Celcuity 股票，交易平均价格为 120.03 美元，总交易额为 2,400,600.00 美元。出售完成后，该董事在公司持有 90,000 股，价值 10,802,700 美元。此次交易使其持股减少了 18.18%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接获取。公司内部人士持有公司股票的 15.78%。</p>
</div><h2>Hedge Funds Weigh In On Celcuity</h2>
<div class="lb-trans"><h2>对 Celcuity 的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning acquired a new stake in Celcuity during the 2nd quarter worth $177,000. Intech Investment Management LLC lifted its stake in shares of Celcuity by 5.2% in the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company's stock valued at $198,000 after purchasing an additional 734 shares during the period. Rhumbline Advisers boosted its position in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company's stock worth $570,000 after purchasing an additional 503 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Celcuity during the second quarter worth $169,000. Finally, Saturn V Capital Management LP grew its stake in shares of Celcuity by 8.4% during the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company's stock worth $15,827,000 after purchasing an additional 91,843 shares during the period. 63.33% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>多家对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Creative Planning 在第二季度获得了 Celcuity 的新股份，价值 177,000 美元。Intech Investment Management LLC 在第二季度将其在 Celcuity 的股份提高了 5.2%。Intech Investment Management LLC 目前持有 14,855 股该公司的股票，价值 198,000 美元，此前在该期间又购买了 734 股。Rhumbline Advisers 在第二季度将其在 Celcuity 的持股增加了 1.2%。Rhumbline Advisers 目前持有 42,697 股该公司的股票，价值 570,000 美元，此前在上个季度又购买了 503 股。XTX Topco Ltd 在第二季度获得了 Celcuity 的新股份，价值 169,000 美元。最后，Saturn V Capital Management LP 在第二季度将其在 Celcuity 的持股增加了 8.4%。Saturn V Capital Management LP 目前持有 1,185,520 股该公司的股票，价值 15,827,000 美元，此前在该期间又购买了 91,843 股。63.33% 的股票由机构投资者持有。</p>
</div><h2>About Celcuity</h2>
<div class="lb-trans"><h2>关于 Celcuity</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.</p>
<div class="lb-trans"><p>Celcuity, Inc 是一家临床阶段的生物技术公司，专注于精准肿瘤学诊断。该公司开发和商业化预测性生物标志物检测，旨在识别哪些患者最有可能从靶向癌症疗法中受益。通过将肿瘤细胞的功能特征与分子分析相结合，Celcuity 旨在优化治疗选择并改善实体肿瘤患者的治疗效果。</p>
</div><p>Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.</p>
<div class="lb-trans"><p>Celcuity 的专有平台通过使用外部检测评估肿瘤细胞对各种治疗药物的敏感性，测量 DNA 损伤反应和其他关键通路。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Celcuity</li>
<li>The $8,000 Gold Call Every Retirement Saver Needs to Read Right Now</li>
<li>A personal warning from Martin Weiss (Please read)</li>
<li>Elon Musk: This Could Turn $100 into $100,000</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>America’s gold reserves are priced at $42. The real price is $6,000+.</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Celcuity</li>
<li>每位退休储蓄者现在需要阅读的 8,000 美元黄金看涨期权</li>
<li>马丁·韦斯的个人警告（请阅读）</li>
<li>埃隆·马斯克：这可能将 100 美元变成 100,000 美元</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>美国的黄金储备定价为 42 美元。真实价格为 6,000 美元以上。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CELC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celcuity Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Celcuity 吗？</h2>
</div><p>Before you consider Celcuity, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Celcuity 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Celcuity 并不在名单上。</p>
</div><p>While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Celcuity 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Celcuity, Inc.（NASDAQ:CELC）被分析师一致推荐为 “适度买入”